Showing results (31-40 of 66) with videos related to
Sort By:
Pageof 7
Investigational New Drugs|September 20, 2001
Dolastatin-10 in metastatic melanoma: a phase II and pharmokinetic trial of the California Cancer ConsortiumK Margolin, J Longmate, T W Synold, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 18, 2001
Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanomaP Lee, F Wang, J Kuniyoshi, et al.Cancer Investigation|March 11, 1999
Cisplatin and infusional cytosine arabinoside for the treatment of colorectal adenocarcinoma: a phase II trialM Tetef, L Leong, C Ahn, et al.Blood|September 1, 1992
High-dose chemoradiotherapy followed by autologous bone marrow transplantation as consolidation therapy during first complete remission in adult patients with poor-risk aggressive lymphoma: a pilot studyA Nademanee, G M Schmidt, M R O'Donnell, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1989
A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanomaJ P Dutcher, S Creekmore, G R Weiss, et al.Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|February 1, 1994
Phase II studies of recombinant human interleukin-4 in advanced renal cancer and malignant melanomaK Margolin, F R Aronson, M Sznol, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 23, 2015
Bevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumorsY Nieto, S-M Tu, R Bassett, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1993
Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanomaJ A Sparano, R I Fisher, M Sunderland, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 1, 1997
Prospective randomized trial of lisofylline for the prevention of toxicities of high-dose interleukin 2 therapy in advanced renal cancer and malignant melanomaK Margolin, M Atkins, J Sparano, et al.ESMO Open|August 30, 2021
Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United StatesP Jain, J Gutierrez Bugarin, A Guha, et al.Pageof 7